Duggan, Mark E. et al. published their patent in 1998 |CAS: 201811-20-3

The Article related to phenoxyalkanoic acid preparation formulation fibrinogen antagonist, platelet aggregation inhibitor phenoxyalkanoic acid preparation, bone resorption inhibitor phenoxyalkanoic acid preparation, thrombus treatment phenoxyalkanoic acid preparation formulation, embolus treatment phenoxyalkanoic acid preparation formulation and other aspects.COA of Formula: C11H14N2O5

On January 8, 1998, Duggan, Mark E.; Egbertson, Melissa S.; Hartman, George D.; Young, Steven D.; Ihle, Nathan C. published a patent.COA of Formula: C11H14N2O5 The title of the patent was Preparation of heterocyclyl-substituted phenoxyalkanoic acids as fibrinogen receptor antagonists. And the patent contained the following:

The title compounds X-Y-Z-A-B [I; X = (un)substituted 5-7- membered aromatic or nonaromatic ring, having 1-3 heteroatoms selected from N, O, and S, (un)substituted 9-10 membered fused aromatic or nonaromatic ring, having 1-3 heteroatoms selected from N, O, and S; Y = (un)substituted 5-6 membered aromatic or nonaromatic ring, having 0-3 heteroatoms selected from N, O, and S; XY = II, III, IV, V; Z = C(O)NR4, N(R4)C(O), CH2CH2, CH:CH, etc.; R4 = H, C1-4 alkyl, C3-6 cycloalkyl; A = (un)substituted 5-6 membered aromatic ring, having 0-3 heteroatoms selected from N, O, and S, 9-10 membered fused aromatic ring having 0-3 heteroatoms (N, O, and S); B = C(CH2)mCO2R9, (CH2)nCO2R9, CH(R8)(CH2)pCO2R9, OCH(R8)(CH2)pCO2R9 (wherein m = 1-3; n = 0-3; p = 0-3; R8 = H, aryl, amino, etc.; R9 = H, aryl, C1-8 alkyl, etc.)], useful in inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus or embolus formation, inhibiting osteoclast mediated bone resorption, inhibiting angiogenesis, and in inhibiting tumor growth, were prepared and formulated. Thus, a few-step detailed synthesis of the acid VI which showed IC50 in the range between 10 nM and 50 mM against ADP-stimulated platelet aggregation, was described. The experimental process involved the reaction of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate(cas: 201811-20-3).COA of Formula: C11H14N2O5

The Article related to phenoxyalkanoic acid preparation formulation fibrinogen antagonist, platelet aggregation inhibitor phenoxyalkanoic acid preparation, bone resorption inhibitor phenoxyalkanoic acid preparation, thrombus treatment phenoxyalkanoic acid preparation formulation, embolus treatment phenoxyalkanoic acid preparation formulation and other aspects.COA of Formula: C11H14N2O5

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics